The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The nontuberculous mycobacterial infection market has witnessed robust growth, with its size surging from $13.43 billion in 2023 to a projected $14.25 billion in 2024, reflecting a Compound Annual Growth Rate (CAGR) of 6.1%. This expansion can be attributed to advancements in diagnostics, an aging population, increased awareness of cystic fibrosis, and the use of immunosuppressive medications.

Current Market Dynamics
Anticipated to maintain strong growth, the nontuberculous mycobacterial infection market is expected to reach $18.17 billion by 2028, demonstrating a CAGR of 6.3%. The surge in the forecast period is fueled by developments in antimicrobial drug research, heightened awareness of nontuberculous mycobacterial infections (NTM), progress in genetic research, and the integration of telehealth and remote monitoring. Key trends include personalized treatment approaches, regulatory focus, the emergence of combination therapies, and the integration of digital health tools.

Rising Prevalence of COPD Driving Market Growth

Understanding the Connection
The escalating prevalence of chronic obstructive pulmonary disease (COPD) is poised to drive the growth of the nontuberculous mycobacterial infection market. COPD, a chronic respiratory condition characterized by persistent airflow limitation, is associated with a more pronounced decline in lung function in patients with NTM infections. The weakened immune system and damaged lung tissue in COPD patients make them more susceptible to NTM bacteria.

Statistics and Impact
A report by The Scottish Public Health Observatory reveals a concerning increase in COPD rates between 2021 and 2022. Male rates rose from 83.2 to 97.6 per 100,000 persons, while female rates increased from 72.6 to 97.3. This rise in COPD prevalence contributes significantly to the growth of the nontuberculous mycobacterial infection market.

Leading Players in the Market

Industry Giants
Major players shaping the nontuberculous mycobacterial infection market include Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, and several others. These industry leaders play a pivotal role in driving innovations and contributing to market growth through research and development.

View More On The Nontuberculous Mycobacterial Infection Market Report 2023 – https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Innovations in Treatment Approvals
Strategic Approaches
Companies in the nontuberculous mycobacterial infection market adopt innovative practices for treatment approvals to maintain their market positions. In June 2021, Paratek Pharmaceuticals Inc. received approval for the expansion of NUZYRA’s indication to treat community-acquired bacterial pneumonia (CABP) in adults. NUZYRA, a modernized tetracycline, has shown efficacy against a spectrum of bacteria, including drug-resistant strains.

Fast Track Designation
The Food and Drug Administration granted Fast Track designation for NUZYRA in July 2022 to treat nontuberculous mycobacterial (NTM) lung disease due to MAC (Mycobacterium avium complex). This highlights the strategic importance of fast-tracking innovative treatments for NTM infections.

Strategic Collaborations: Qurient and TB Alliance
Pioneering Drug Development
In February 2023, Qurient Co. Ltd., a biotech company based in Korea, collaborated with TB Alliance to develop telacebec, a drug designed to treat tuberculosis and other nontuberculous mycobacteria (NTM) infections. This partnership grants TB Alliance the global license for Telacebec, indicating its authority to continue development and market the drug internationally.

Market Segmentation

In-Depth Analysis

The nontuberculous mycobacterial infection market is segmented based on several factors:

1. Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2. Route of Administration: Oral, Parenteral, Other Routes
3. Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Focus: North America Takes the Lead
In 2023, North America emerged as the largest region in the nontuberculous mycobacterial infection market. Moreover, it is projected to be the fastest-growing region in the forecast period.

Top of Form

Request A Sample Of The Global Nontuberculous Mycobacterial Infection Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=13020&type=smp

The Nontuberculous Mycobacterial Infection Global Market Report 2023  provides a comprehensive overview on the nontuberculous mycobacterial infection market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the nontuberculous mycobacterial infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Tuberculosis Diagnostics Global Market Report 2023
Chronic Cough Global Market Report 2023
Chronic Cough Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model